Probiotics for disease prevention: A focus on ventilator-associated pneumonia;Probióticos para la Prevención de Enfermedades: Un Enfoque en la Neumonía Asociada a Ventilación Mecánica

Annals of Pharmacotherapy

Volumn 45, Issue 11, 2011, Pages 1425-1432

  Bailey, Jennifer L ^a   Yeung, Siu Yan ^a  

^a UNIVERSITY OF MARYLAND MEDICAL CENTER   (United States)

Author keywords

Probiotics; Ventilator associated pneumonia

Indexed keywords

PROBIOTIC AGENT; SYNBIOTIC AGENT;

ABSENCE OF SIDE EFFECTS; ACINETOBACTER; ANTIMICROBIAL ACTIVITY; ARTIFICIAL VENTILATION; BACTERIAL COLONIZATION; BIFIDOBACTERIACEAE; CLINICAL EVALUATION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; ENDOTRACHEAL INTUBATION; HUMAN; INTENSIVE CARE UNIT; LACTOBACILLUS; LACTOBACILLUS RHAMNOSUS; LENGTH OF STAY; MEDLINE; META ANALYSIS (TOPIC); METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MICROBIOLOGICAL EXAMINATION; MORTALITY; PHYSICAL EXAMINATION; PRIORITY JOURNAL; PROPHYLAXIS; PSEUDOMONAS AERUGINOSA; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SACCHAROMYCES; SUPPLEMENTATION; THORAX RADIOGRAPHY; VENTILATOR ASSOCIATED PNEUMONIA;

HUMANS; META-ANALYSIS AS TOPIC; PILOT PROJECTS; PNEUMONIA, VENTILATOR-ASSOCIATED; PROBIOTICS; PROSPECTIVE STUDIES; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 80155167220     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1Q241     Document Type: Review

References (51)

1. American Thoracic Society: Infectious Diseases Society of America. Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. Am J Respir Crit Care Med 2005;171:388-416.
2. Fagon JY, Chastre J, Hance AJ, Montravers P, Novara A, Gibert C. Nosocomial pneumonia in ventilated patients: a cohort study evaluating attributable mortality and hospital stay. Am J Med 1993;94:281-8.
3. Heyland DK, Cook DJ, Griffith L, Keenan SP, Brun-Buisson C. The at-tributable morbidity and mortality of ventilator-associated pneumonia in the critically ill patient. The Canadian Critical Trials Group. Am J Respir Crit Care Med 1999;159:1249-56.
4. Bercault N, Boulain T. Mortality rate attributable to ventilator-associated nosocomial pneumonia in an adult intensive care unit: a prospective case-control study. Crit Care Med 2001;29:2303-9.
5. Craven DE, De Rosa FG, Thornton D. Nosocomial pneumonia: emerging concepts in diagnosis, management, and prophylaxis. Curr Opin Crit Care 2002;8:421-9.
6. Rello J, Ollendorf DA, Oster G, et al. Epidemiology and outcomes of ventilator-associated pneumonia in a large US database. Chest 2002; 122:2115-21.
7. Kollef MH, Shorr A, Tabak YP, Gupta V, Liu LZ, Johannes RS. Epidemiology and outcomes of health-care-associated pneumonia: results from a large US database of culture-positive pneumonia. Chest 2005; 128:3854-62.
8. Tejerina E, Frutos-Vivar F, Restrepo MI, et al. Incidence, risk factors, and outcome of ventilator-associated pneumonia. J Crit Care 2006;21:56-65.
9. Bonten MJ. Healthcare epidemiology: ventilator-associated pneumonia preventing the inevitable. Clin Infect Dis 2011;52:115-21.
10. Coffin SE, Klompas M, Classen D, et al. Strategies to prevent ventilator-associated pneumonia in acute care hospitals. Infect Control Hosp Epidemiol 2008;29(suppl 1):S31-40.
11. Berra L, Sampson J, Fumagalli J, Panigada M, Kolobow T. Alternative approaches to ventilator-associated pneumonia prevention. Minerva Anestesiol 2011;77:323-33.
12. Klompas M. Prevention of ventilator-associated pneumonia. Expert Rev Anti Infect Ther 2010;8:791-800.
13. Safdar N, Crnich CJ, Maki DG. The pathogenesis of ventilator-associated pneumonia: its relevance to developing effective strategies for preven-tion. Respir Care 2005;50:725-41.
14. FAO/WHO. 2002. Guidelines for the evaluation of probiotics in food. Report of a Joint FAO/WHO Working Group on Drafting Guidelines for the Evaluation of Probiotics in Food. London, Ontario, Canada, April 30-May 1, 2002.
15. Forestier C, Guelon D, Cluytens V, Gillart T, Sirot J, De Champs C. Oral probiotic and prevention of Pseudomonas aeruginosa infections: a randomized, double-blind, placebo-controlled pilot study in intensive care unit patients. Crit Care 2008;12:R69.
16. Klarin B, Molin G, Jeppsson B, Larsson A. Use of the probiotic Lactobacillus plantarum 299 to reduce pathogenic bacteria in the oropharynx of intubated patients: a randomised controlled open pilot study. Crit Care 2008;12:R136.
17. Chastre J, Fagon JY. Ventilator-associated pneumonia. Am J Respir Crit Care Med 2002;165:867-903.
18. Koenig SM, Truwit JD. Ventilator-associated pneumonia: diagnosis, treatment, and prevention. Clin Microbiol Rev 2006;19:637-57.
19. Vanderhoof JA, Young R. Probiotics in the United States. Clin Infect Dis 2008;46(suppl 2):S67-72.
20. Williams NT. Probiotics. Am J Health Syst Pharm 2010;67:449-58.
21. Boyle RJ, Robins-Browne RM, Tang ML. Probiotic use in clinical practice: what are the risks? Am J Clin Nutr 2006;83:1256-64.
22. Sanders ME. Use of probiotics and yogurts in maintenance of health. J Clin Gastroenterol 2008;42(suppl 2):S71-4.
23. Senok AC, Ismaeel AY, Botta GA. Probiotics: facts and myths. Clin Microbiol Infect 2005;11:958-66.
24. Reid G, Jass J, Sebulsky MT, McCormick JK. Potential uses of probiotics in clinical practice. Clin Micobiol Rev 2003;16:658-672.
25. Isakow W, Morrow LE, Kollef MH. Probiotics for preventing and treating nosocomial infections: review of current evidence and recommendations. Chest 2007;132:286-94.
26. McNabb B, Isakow W. Probiotics for the prevention of nosocomial pneumonia: current evidence and opinions. Curr Opin Pulm Med. 2008;14:169-75
27. Ng SC, Hart AL, Kamm MA, Stagg AJ, Knight SC. Mechanisms of action of probiotics: recent advances. Inflamm Bowel Dis 2009;15:300-10.
28. Perdigón G, Maldonado Galdeano C, Valdez JC, Medici M. Interaction of lactic acid bacteria with the gut immune system. Eur J Clin Nutr 2002; 56:S21-6.
29. Vitiñi E, Alvarez S, Medina M, Medici M, de Budeguer MV, Perdigón G. Gut mucosal immunostimulation by lactic acid bacteria. Biocell 2000;24: 223-32.
30. Alberda C, Gramlich L, Meddings J, et al. Effects of probiotic therapy in critically ill patients: a randomized, double-blind, placebo-controlled trial. Am J Clin Nutr 2007;85:816-23.
31. Jain PK, McNaught CE, Anderson AD, MacFie J, Mitchell CJ. Influence of symbiotic containing Lactobacillus acidophilus La5, Bifidobacterium lactis Bb 12, Streptococcus thermophilus, Lactobacillus bulgaricus and oligofructose on gut barrier function and sepsis in critically ill patients: a randomized controlled trial. Clin Nutr 2004;23:467-75.
32. Kotzampassi K, Giamarellos-Bourboulis EJ, Voudouris A, Kazamias P, Eleftheriadis E. Benefits of a synbiotic formula (Synbiotic 2000 Forte) in critically ill trauma patients: early results of a randomized controlled trial. World J Surg 2006;30:1848-55.
33. Spindler-Vesel A, Bengmark S, Vovk I, Cerovic O, Kompan L. Synbiotics, prebiotics, glutamine, or peptide in early enteral nutrition: a randomized study in trauma patients. JPEN J Parenter Enteral Nutr 2007;31: 119-26.
34. Rayes N, Seehofer D, Hansen S, et al. Early enteral supply of Lactobacillus and fiber versus selective bowel decontamination: a controlled trial in liver transplant recipients. Transplantation 2002;71:123-7.
35. Watkinson PJ, Barber VS, Dark P, Young JD. The use of preproand synbiotics in adult intensive care unit patients: systematic review. Clin Nutr 2007;26:182-92.
36. Morrow LE. Probiotics in the intensive care unit. Curr Opin Crit Care 2009;15:144-8.
37. Hojsak I, Abdovic S, Szajewska H, Milosević M, Krznaric Z, Kolacek S. Lactobacillus GG in the prevention of nosocomial gastrointestinal and respiratory tract infections. Pediatrics 2010;125:1171-7.
38. Forestier C, Guelon D, Cluytens V, Gillart T, Sirot J, De Champs C. Oral probiotic and prevention of Pseudomonas aeruginosa infections: a randomized, double-blind, placebo-controlled pilot study in intensive care unit patients. Crit Care 2008;12:R69.
39. Klarin B, Molin G, Jeppsson B, Larsson A. Use of the probiotic Lactobacillus plantarum 299 to reduce pathogenic bacteria in the oropharynx of intubated patients: a randomised controlled open pilot study. Crit Care 2008;12:R136.
40. Knight DJ, Gardiner D, Banks A, et al. Effect of synbiotic therapy on the incidence of ventilator associated pneumonia in critically ill patients: a randomized, double-blind, placebo-controlled trial. Intensive Care Med 2009; 35:854-61.
41. Morrow LE, Kollef MH, Casale TB. Probiotic prophylaxis of ventilator-associated pneumonia: a blinded, randomized, controlled trial. Am J Respir Crit Care Med 2010;182:1058-64.
42. Barraud D, Blard C, Hein F, et al. Probiotics in the critically ill patient: a double blind, randomized, placebo-controlled trial. Intensive Care Med 2010;36:1540-7.
43. Besselink MG, van Santvoort HC, Buskens E, et al. Probiotic prophylax-is in predicted severe acute pancreatitis: a randomised, double-blind, placebo-controlled trial. Lancet 2008;371:651-9.
44. Siempos II, Ntaidow TK, Falagas ME. Impact of the administration of probiotics on the incidence of ventilator-associated pneumonia: a metaanalysis of randomized controlled trials. Crit Care Med 2010;38:954-62.
45. Liong MT. Safety of probiotics: translocation and infection. Nutr Rev 2008;66:192-202.
46. Weese JS. Evaluation of deficiencies in labeling of commercial probiotics. Can Vet J 2003;44:982-3.
47. Hamilton-Miller JM, Shah S, Winkler JT. Public health issues arising from microbiological and labeling quality of foods and supplements containing probiotic microorganisms. Public Health Nutr 1999;2:334-9.
48. Snydman DR. The safety of probiotics. Clin Infect Dis 2008;46(suppl 2):S104-11.
49. Zhou JS, Shu Q, Rutherford KJ, et al. Safety assessment of potential probiotic lactic acid bacteria strains Lactobacillus rhamnosus HN001, Lb. acidophilus HN017 and Bifidobacterium lactis HN019 in BALB/c mice. Int J Food Microbiol 2000;56:87-96.
50. Asahara T, Takahashi M, Nomoto K, et al. Assessment of safety of Lactobacillus strains based on resistance to host innate defense mechanisms. Clin Diagn Lab Immunol 2003;10:169-73.
51. Berg RD, Garlington AW. Translocation of certain indigenous bacteria from the gastrointestinal tract to the mesenteric lymph nodes and other organs in the gnotobiotic mouse model. Infect Immun 1979;23:401-11.